Full Press Release Details
Bio, Inc. to Participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September
Calif., Sep. 14, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology
company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today
management will participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September
Management will be available for
virtual one-on-one meetings during the conference. To schedule a meeting with management, please contact your conference representative
Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that
target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic
target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ),
Alzheimer's (XPro595), and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed
at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's
product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid
tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward-Looking Statements
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this
press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.
Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. INB03 , Quellor , XPro1595, LIVNate , and INKmune
are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any
specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical
trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research
and development, clinical studies and future product commercialization; and, the Company's business, research, product development,
regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in
more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report
on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company
assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after
the date of this release.
David Moss, CFO (858) 964-3720
James Carbonara (646) 755-7412